TargetBeta
HTR1A
5-hydroxytryptamine receptor 1A · also 5-HT1A, ADRB2RL1, ADRBRL1 · 5-hydroxytryptamine receptors, G protein-coupled
5 programs in company-led studies act on HTR1A, from 3 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 1312 running | DRD2, HTR2A | ChEMBL |
| Vortioxetinerule | H. Lundbeck | phase 4 | 621 running | HTR3A, SLC6A4, SMS | ChEMBL |
| brexpiprazolerule | Otsuka | phase 4 | 700 running | DRD2, HTR2A | ChEMBL |
| ulotarontrule | Otsuka | phase 3 | 305 running | TAAR1 | ChEMBL |
| ABBV-932 | AbbVie | phase 2 | 103 running | DRD2, DRD3 | the company's pipeline |
Conditions their studies are in
- Depressive Disorder, Major, 4 programs
- Generalized Anxiety Disorder, 3 programs
- Schizophrenia, 3 programs
- Bipolar Disorder, 2 programs
- Alzheimer Disease, 1 program
- Anxiety Disorders, 1 program
- Attention Deficit Disorder with Hyperactivity, 1 program
- Autistic Disorder, 1 program
- Depression, 1 program
- Mania, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026ABBV-932 · AbbVie · phase 2 · NCT06846320
- Sep 5, 2027Aripiprazole · Otsuka · phase 4 · NCT07547384
- Mar 2028ulotaront · Otsuka · phase 3 · NCT07225712
- Sep 30, 2029Vortioxetine · H. Lundbeck · phase 4 · NCT07204314
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.